An update of a phase II study of paclitaxel in advanced or recurrent squamous cell cancer of the cervix

Andrzej P. Kudelka; Rodger Winn; Creighton L. Edwards; G. Downey; Harvey Greenberg; S. R. Dakhil; Ralph S. Freedman; Salvatore LoCoco; J. Umbreit; James E. Delmore; Susan Arbuck; Evelyne Loyer; Patsy Gacrama; Rebecca Fueger; John J. Kavanagh

doi:10.1097/00001813-199708000-00002

An update of a phase II study of paclitaxel in advanced or recurrent squamous cell cancer of the cervix

Andrzej P. Kudelka, Rodger Winn, Creighton L. Edwards, G. Downey, Harvey Greenberg, S. R. Dakhil, Ralph S. Freedman, Salvatore LoCoco, J. Umbreit, James E. Delmore, Susan Arbuck, Evelyne Loyer, Patsy Gacrama, Rebecca Fueger, John J. Kavanagh

Research output: Contribution to journal › Article › peer-review

56 Scopus citations

Abstract

Thirty-two evaluable patients with squamous cell cancer of the cervix were treated with i.v. paclitaxel 250 mg/m² over 3 h every 21 days. They received standard premedications and granulocyte colony stimulating factor (G-CSF) support (5 μg/kg/day). Median (range) age was 49 (29-81) years and performance status Zubrod was 1 (0-2). One patient had a complete response and seven patients had a partial response (25%, 95% CI 8-38%). The median survival was 7.3 months. Granulocytopenia was brief and non-cumulative. G-CSF was used for a median (range) of 8 (1-15) days per cycle. In conclusion: paclitaxel is active in patients with squamous cell cancer of the cervix and is well tolerated in this dose schedule with G-CSF support.

Original language	English (US)
Pages (from-to)	657-661
Number of pages	5
Journal	Anti-Cancer Drugs
Volume	8
Issue number	7
DOIs	https://doi.org/10.1097/00001813-199708000-00002
State	Published - 1997
Externally published	Yes

Keywords

Cervix cancer
Granulocyte colony stimulating factor
Paclitaxel

ASJC Scopus subject areas

Oncology
Pharmacology
Pharmacology (medical)
Cancer Research

Access to Document

10.1097/00001813-199708000-00002

Cite this

Kudelka, A. P., Winn, R., Edwards, C. L., Downey, G., Greenberg, H., Dakhil, S. R., Freedman, R. S., LoCoco, S., Umbreit, J., Delmore, J. E., Arbuck, S., Loyer, E., Gacrama, P., Fueger, R., & Kavanagh, J. J. (1997). An update of a phase II study of paclitaxel in advanced or recurrent squamous cell cancer of the cervix. Anti-Cancer Drugs, 8(7), 657-661. https://doi.org/10.1097/00001813-199708000-00002

Kudelka, AP, Winn, R, Edwards, CL, Downey, G, Greenberg, H, Dakhil, SR, Freedman, RS, LoCoco, S, Umbreit, J, Delmore, JE, Arbuck, S, Loyer, E, Gacrama, P, Fueger, R & Kavanagh, JJ 1997, 'An update of a phase II study of paclitaxel in advanced or recurrent squamous cell cancer of the cervix', Anti-Cancer Drugs, vol. 8, no. 7, pp. 657-661. https://doi.org/10.1097/00001813-199708000-00002

@article{5dd80595f90640f7afef18765b047420,

title = "An update of a phase II study of paclitaxel in advanced or recurrent squamous cell cancer of the cervix",

abstract = "Thirty-two evaluable patients with squamous cell cancer of the cervix were treated with i.v. paclitaxel 250 mg/m2 over 3 h every 21 days. They received standard premedications and granulocyte colony stimulating factor (G-CSF) support (5 μg/kg/day). Median (range) age was 49 (29-81) years and performance status Zubrod was 1 (0-2). One patient had a complete response and seven patients had a partial response (25%, 95% CI 8-38%). The median survival was 7.3 months. Granulocytopenia was brief and non-cumulative. G-CSF was used for a median (range) of 8 (1-15) days per cycle. In conclusion: paclitaxel is active in patients with squamous cell cancer of the cervix and is well tolerated in this dose schedule with G-CSF support.",

keywords = "Cervix cancer, Granulocyte colony stimulating factor, Paclitaxel",

author = "Kudelka, {Andrzej P.} and Rodger Winn and Edwards, {Creighton L.} and G. Downey and Harvey Greenberg and Dakhil, {S. R.} and Freedman, {Ralph S.} and Salvatore LoCoco and J. Umbreit and Delmore, {James E.} and Susan Arbuck and Evelyne Loyer and Patsy Gacrama and Rebecca Fueger and Kavanagh, {John J.}",

year = "1997",

doi = "10.1097/00001813-199708000-00002",

language = "English (US)",

volume = "8",

pages = "657--661",

journal = "Anti-Cancer Drugs",

issn = "0959-4973",

publisher = "Lippincott Williams and Wilkins",

number = "7",

}

TY - JOUR

T1 - An update of a phase II study of paclitaxel in advanced or recurrent squamous cell cancer of the cervix

AU - Kudelka, Andrzej P.

AU - Winn, Rodger

AU - Edwards, Creighton L.

AU - Downey, G.

AU - Greenberg, Harvey

AU - Dakhil, S. R.

AU - Freedman, Ralph S.

AU - LoCoco, Salvatore

AU - Umbreit, J.

AU - Delmore, James E.

AU - Arbuck, Susan

AU - Loyer, Evelyne

AU - Gacrama, Patsy

AU - Fueger, Rebecca

AU - Kavanagh, John J.

PY - 1997

Y1 - 1997

N2 - Thirty-two evaluable patients with squamous cell cancer of the cervix were treated with i.v. paclitaxel 250 mg/m2 over 3 h every 21 days. They received standard premedications and granulocyte colony stimulating factor (G-CSF) support (5 μg/kg/day). Median (range) age was 49 (29-81) years and performance status Zubrod was 1 (0-2). One patient had a complete response and seven patients had a partial response (25%, 95% CI 8-38%). The median survival was 7.3 months. Granulocytopenia was brief and non-cumulative. G-CSF was used for a median (range) of 8 (1-15) days per cycle. In conclusion: paclitaxel is active in patients with squamous cell cancer of the cervix and is well tolerated in this dose schedule with G-CSF support.

AB - Thirty-two evaluable patients with squamous cell cancer of the cervix were treated with i.v. paclitaxel 250 mg/m2 over 3 h every 21 days. They received standard premedications and granulocyte colony stimulating factor (G-CSF) support (5 μg/kg/day). Median (range) age was 49 (29-81) years and performance status Zubrod was 1 (0-2). One patient had a complete response and seven patients had a partial response (25%, 95% CI 8-38%). The median survival was 7.3 months. Granulocytopenia was brief and non-cumulative. G-CSF was used for a median (range) of 8 (1-15) days per cycle. In conclusion: paclitaxel is active in patients with squamous cell cancer of the cervix and is well tolerated in this dose schedule with G-CSF support.

KW - Cervix cancer

KW - Granulocyte colony stimulating factor

KW - Paclitaxel

UR - http://www.scopus.com/inward/record.url?scp=9844223395&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=9844223395&partnerID=8YFLogxK

U2 - 10.1097/00001813-199708000-00002

DO - 10.1097/00001813-199708000-00002

M3 - Article

C2 - 9311440

AN - SCOPUS:9844223395

SN - 0959-4973

VL - 8

SP - 657

EP - 661

JO - Anti-Cancer Drugs

JF - Anti-Cancer Drugs

IS - 7

ER -

An update of a phase II study of paclitaxel in advanced or recurrent squamous cell cancer of the cervix

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this